Proactive investors

Renovo Group (LSE:RNVO) is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. The company aims to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need. Renovo Group’s pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.

Renovo has previously reported statistically significant efficacy data for Prevascar® in the reduction of scarring in the skin. A new proof of concept clinical study has started in volunteers of African Ancestral Group origin using an improved clinical drug product. Interim data should be available during H1 2011. Juvista is currently in an EU P3 trial scheduled to report in H1 2011. Adaprev™ is being developed as a Class III medical device and the first trial for the reduction of tendon adhesions is underway and is due to report results in H2 2011. Renovo is actively seeking to partner Juvidex® as a cosmetic ingredient for the improvement of skin appearance and acceleration of healing.